Unlock stock picks and a broker-level newsfeed that powers Wall Street.
Cboe UK CHF

Basilea Pharmaceutica AG (BSLNZ.XC)

Compare
42.62
-0.62
(-1.45%)
At close: April 3 at 4:19:45 PM GMT+1
Currency in CHF All numbers in thousands
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
157,634
157,634
147,765
148,122
127,629
Cost of Revenue
26,794
26,794
24,603
24,072
24,054
Gross Profit
130,840
130,840
123,162
124,050
103,575
Operating Expense
108,932
108,932
102,349
121,042
124,986
Operating Income
21,908
21,908
20,813
3,008
-21,411
Net Non Operating Interest Income Expense
-9,512
-9,512
-9,522
-8,085
-7,977
Pretax Income
10,461
10,461
12,102
-6,794
-14,667
Tax Provision
10
10
-45
37
55
Net Income Common Stockholders
10,451
10,451
12,147
-6,831
-14,722
Diluted NI Available to Com Stockholders
10,451
10,451
12,147
-6,831
-14,722
Basic EPS
0.87
0.87
1.02
-0.58
-1.43
Diluted EPS
0.86
0.86
1.02
-0.58
-1.43
Basic Average Shares
11,991.39
11,991.39
11,860.96
11,681.98
10,281.48
Diluted Average Shares
12,143.08
12,143.08
11,943.53
11,681.98
10,281.48
Total Operating Income as Reported
19,205
19,205
18,543
1,187
-8,222
Total Expenses
135,726
135,726
126,952
145,114
149,040
Net Income from Continuing & Discontinued Operation
10,451
10,451
12,147
-6,831
-14,722
Normalized Income
10,451
10,451
12,147
-6,351.41
-27,258.40
Interest Income
1,690
1,690
326
66
104
Interest Expense
11,202
11,202
9,848
8,151
7,589
Net Interest Income
-9,512
-9,512
-9,522
-8,085
-7,977
EBIT
21,663
21,663
21,950
1,357
-7,078
EBITDA
23,240
23,240
23,047
2,111
-5,888
Reconciled Cost of Revenue
26,794
26,794
24,603
24,072
24,054
Reconciled Depreciation
1,577
1,577
1,097
754
1,190
Net Income from Continuing Operation Net Minority Interest
10,451
10,451
12,147
-6,831
-14,722
Total Unusual Items Excluding Goodwill
--
--
-41
-482
14,721
Total Unusual Items
--
--
-41
-482
14,721
Normalized EBITDA
23,240
23,240
23,047
2,593
-20,609
Tax Rate for Calcs
--
--
0
0
0
Tax Effect of Unusual Items
--
--
--
-2.41
2,184.60
12/31/2020 - 11/24/2009

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade